How Biotech Startups Get Funded

A software founder and a biotech founder use the same vocabulary — seed, Series A, dilution, exit — and mean substantially different things by it.

The software company can build a product in months, sell it, and fund growth from revenue if it has to. The biotech company may spend eight years and several hundred million dollars before it knows whether its lead asset works, with a single readout capable of ending the company on a Tuesday morning.

That difference shapes every financing decision. This guide covers how biotech capital actually works, who funds each stage, why non-dilutive money matters so much more here, and what investors are really underwriting.

1. Why the Financing Structure Is Different

• Binary risk. A clinical readout succeeds or fails. There is rarely a pivot that salvages a failed mechanism, which means the risk cannot be diversified away inside one company — only across a portfolio.
• Very long timelines. Discovery through approval commonly runs a decade or more. That does not fit comfortably inside a ten-year fund life, which is why biotech investors think hard about the exit long before it happens.
• Enormous capital requirements. Late-stage clinical trials are among the most expensive activities a private company can undertake.
• No revenue for most of that period, so every efficiency metric used in software — burn multiple, CAC payback, net revenue retention — is simply inapplicable. Our guide to the metrics investors underwrite describes a world biotech does not live in.
• Regulated, gated progress. The FDA and its equivalents define the milestones. You cannot design your own.

The consequence is that biotech financing is organised around de-risking events rather than around growth.

2. The Stages, and Who Funds Each

Discovery and target validation

Frequently funded inside a university on federal research grants, before a company exists. The company is formed to license the resulting intellectual property from the institution — which makes the tech transfer negotiation one of the most consequential early events. Terms typically include an upfront fee, equity, milestone payments and royalties, and they sit on the asset permanently.

Funders: academic grants, translational funds, university venture funds, angels with domain expertise.

Preclinical

Lead optimisation, animal studies, toxicology, manufacturing process development, and preparation of an IND filing. This is where seed and Series A capital goes.

Funders: specialist biotech seed funds, venture creation firms that build companies around their own scientific theses, corporate venture arms of pharmaceutical companies, and — importantly — NIH SBIR and STTR awards, which are larger in life sciences than at most other agencies.

Clinical development

Phase I establishes safety in humans. Phase II tests efficacy in patients and is where most programmes fail. Phase III is the large, expensive confirmatory trial.

Funders: Series B and later, crossover investors who invest privately with a public listing in view, pharma partners, and increasingly structured instruments — royalty monetisation and development financing.

Approval and commercialisation

Either a partner takes the asset to market, or the company builds a commercial organisation itself — which is another very large capital requirement and a completely different skill set.

3. Tranched Financing: The Structure That Defines Biotech

A biotech Series A of $60 million is frequently not $60 million arriving at closing. It is commonly structured as an initial tranche, with the balance released on achievement of a defined scientific milestone — an IND clearance, a readout, a manufacturing result.

This is rational, since it lets investors stop funding a failing programme. It also creates specific dynamics founders must understand:

• Define the milestone with total precision. Ambiguity about what counts as success becomes a negotiation at exactly the moment you have least leverage.
• Understand who decides. If the milestone is subject to investor discretion rather than an objective test, you do not have committed capital — you have an option they hold.
• Model the failure case. If the second tranche does not release, how long does the first fund you, and what can you do in that time?
• Watch the pricing. Later tranches sometimes come at the same price despite the company having de-risked substantially, which is a real transfer of value to the investor.

Structure elsewhere in the term sheet matters just as much — liquidation preferences accumulate heavily in capital-intensive sectors, and a company that has raised $300 million has a preference stack that shapes every exit conversation.

4. Non-Dilutive Capital Is a Real Strategy Here

In software, grants are a curiosity. In biotech they can fund years of work.

• NIH SBIR and STTR. Among the largest awards in the federal programme, and specifically designed for the preclinical-to-early-clinical gap. Investigator-initiated, so you propose the work rather than answering a topic.
• Disease foundations and patient advocacy organisations. Many run venture philanthropy arms making grants or investments in programmes targeting their disease, frequently on concessionary terms with royalty rights rather than equity.
• Government preparedness and biodefense programmes, which fund development in areas of strategic interest.
• Translational and academic bridge funds that carry work from lab to company formation.
• Prize competitions and challenge programmes.
• R&D tax credits, which for a company with substantial US research payroll can offset payroll tax and produce actual cash.

A preclinical company that funds two years on grants and enters its Series A with an IND-enabling package has given up nothing and is negotiating from a far stronger position.

5. Pharma Partnerships as Financing

A partnership with a large pharmaceutical company is frequently the single largest financing event in a biotech's life, and it is not an equity round.

The typical structure:

• Upfront payment — cash at signing, non-dilutive
• Research funding — the partner funds ongoing work
• Development and regulatory milestones — payments on defined achievements
• Commercial milestones — payments on sales thresholds
• Royalties on eventual product sales
• Sometimes an equity investment alongside, and sometimes an option to acquire the company or the asset at a pre-agreed price

Headline "deal values" quoted in press releases sum every possible milestone and are close to meaningless. The number that matters is the upfront plus committed research funding — the money that arrives regardless of outcome.

The strategic trade-off is real. A partnership validates the science, funds development and reduces dilution. It also gives away economics on your best asset, can constrain how you develop it, and — if the partner deprioritises the programme after a reorganisation — can leave an asset stranded inside a contract. Negotiate diligence obligations and reversion rights, so an unworked asset comes back to you.

6. What Investors Actually Underwrite

Not traction, because there is none. Instead:

• Mechanism and target validation. Is there credible human evidence — genetic, biomarker, or from related programmes — that modulating this target changes the disease?
• The intellectual property position. Composition of matter claims, freedom to operate, the licence terms from the university, and how long exclusivity actually runs.
• The regulatory path. Which endpoint, which patient population, what precedent exists, and whether any accelerated route applies.
• Team and key opinion leaders. Who is running development, who has done it before, and which clinicians in the field take the science seriously. Investor diligence in biotech is substantially a series of calls to academics.
• Manufacturability. For biologics and cell and gene therapies, chemistry, manufacturing and controls is a frequent and underestimated point of failure.
• Competitive landscape. What else is in development against the same target, and how far ahead is it.
• The capital plan to the next value inflection. Investors think in terms of the next de-risking event, not the next twelve months.

7. Platform Versus Asset

A choice that shapes your entire financing story.

A platform company claims a technology that can generate many programmes. It attracts larger rounds and pharma partnerships, and it can survive a single failure. The risk is that platforms are frequently valued on a lead asset anyway, so a failed lead damages the whole story regardless.

An asset company pursues one or two programmes. Cleaner to evaluate, cheaper to run, easier to acquire. And genuinely binary.

Neither is correct in general. What is a mistake is claiming to be a platform while running a single programme — sophisticated investors identify this immediately, and it costs credibility.

8. Exits

• Acquisition by pharma — the most common outcome, frequently structured with substantial contingent value tied to future milestones. Our guide to selling your company covers why contingent consideration should be discounted heavily.
• IPO — biotech lists earlier relative to revenue than any other sector, frequently pre-revenue on clinical data alone. The window opens and closes with market sentiment, which is why crossover investors who can bridge private and public are so central.
• Reverse merger into a listed shell, common when the IPO window is shut.
• Asset sale or out-licensing, where a programme is sold and the company continues with the rest.
• Royalty monetisation, selling future royalty streams for cash today — increasingly common and genuinely useful for a company with an approved product and no desire to dilute.

Frequently Asked Questions

Can a biotech bootstrap?

Service and tools businesses can — research reagents, software, contract research. A therapeutics company essentially cannot, because clinical trials cannot be funded from a small revenue base. The realistic non-dilutive route for therapeutics is grants plus partnership, not customer revenue.

How much dilution should founders expect?

Considerably more than in software. Multiple large rounds over a decade routinely leave founding teams with a small single-digit percentage by the time of an exit. This is why founder equity terms, refresh grants and management incentive plans matter so much here, and why they should be discussed early rather than discovered late.

Does QSBS apply to biotech companies?

Yes for a qualifying domestic C corporation — biotech is not within the excluded service categories, though a company primarily delivering clinical services rather than developing products is in different territory. Given the very long holding periods in this sector, the Section 1202 five-year test is usually easy to satisfy, and the gross assets ceiling at issuance is the binding constraint for later investors.

What is a venture creation firm?

A firm that originates scientific ideas internally, builds a company around them, seeds it, and installs a management team. Founders join a company that already exists rather than starting one. The economics differ substantially from a conventional founding position, and the terms should be understood clearly before joining.

Should we take corporate venture money early?

It brings validation, deep sector expertise and a potential future partner. It can also signal exclusivity to that partner's competitors and complicate a later auction. Rights of first refusal or first negotiation over your assets are the specific terms to resist — they reduce the competitive tension that produces good exits.

The Bottom Line

Biotech is financed against scientific de-risking events, not growth. Tranched rounds, non-dilutive grants and pharma partnerships do work that equity does in other sectors, and the exit is planned from the beginning because the timelines demand it.

Fund as much preclinical work as you can non-dilutively, define your milestones precisely, and treat the headline number in any partnership announcement as marketing.

Global Capital Network connects life science founders with specialist investors, corporate venture arms and advisors through our network and events. Get in touch.